11:15 AM
 | 
Aug 31, 2018
 |  BC Extra  |  Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed to significantly reduce disease activity as measured by the SLE Responder Index (SRI)-4 response at 12 months.

The double-blind, international trial enrolled 460 patients with moderately to severely active autoantibody-positive SLE who were receiving...

Read the full 322 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >